-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 4, Corning Jereh and CSPC jointly announced that a registered clinical trial (KN026-CSP-001) of the HER2 bispecific antibody KN026 combined with chemotherapy has been applied for by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
KN026-CSP-001 is a randomized, multicenter, phase II/III clinical study to evaluate the effectiveness and safety of KN026 combined with chemotherapy in patients with HER2-positive gastric cancer (including gastric-esophageal junction adenocarcinoma) who have failed first-line treatment , Professor Xu Jianming from the General Hospital of the Chinese People’s Liberation Army served as the principal investigator
Gastric cancer and adenocarcinoma of the gastroesophageal junction are one of the common malignant tumors.
KN026's Phase II study data released at the ASCO annual meeting in 2021 shows that KN026 is effective in treating patients with advanced HER2-positive gastric and gastroesophageal junction adenocarcinoma, regardless of whether the patient has previously received trastuzumab therapy: in patients with high HER2 expression , The objective response rate (ORR) was 55.
Note: The original text has been deleted